Actively Recruiting
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Led by Charite University, Berlin, Germany · Updated on 2025-02-13
26
Participants Needed
1
Research Sites
286 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma
CONDITIONS
Official Title
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed glioblastoma confirmed by pathology according to WHO criteria
- Age between 18 and 70 years
- WHO performance status of 2 or less
- Signed written informed consent
- Adequate blood counts and kidney and liver function (specified lab thresholds)
- Have had subtotal or gross total tumor resection
- MGMT-promotor methylated patients who refused CeTeG/NOA-09 protocol therapy
- Planned for combined radiochemotherapy with total 60 Gy radiation over 6 weeks and temozolomide followed by 6 cycles of maintenance temozolomide chemotherapy
You will not qualify if you...
- Previous cranial radiation therapy
- Cancer treatment with cytostatic therapy, anti-angiogenic drugs, chemotherapy or radiation within past 5 years
- History of cancers or other illnesses limiting life expectancy to less than 5 years
- Postoperative signs of increased brain pressure (midline shift >5mm, papilledema, vomiting, reduced consciousness)
- Unable to have MRI or allergic to MRI/CT contrast agents
- Cannot use radiofrequency electromagnetic field treatment due to implanted devices or metal implants
- Women of childbearing age not using or unable to use effective contraception
- Pregnant patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charité Universitätsmedizin Berlin
Berlin, Germany, 13353
Actively Recruiting
Research Team
P
Pirus Ghadjar, Prof. Dr.
CONTACT
D
David Kaul, PD. Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here